<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Abstract

Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

“…Repurposing of anti-inflammatory biologics such as Itolizumab could play an important role in treating the cytokine storm and complications due to COVID-19 infection and reduce mortality due to cytokine storm complications. Itolizumab is an approved drug in India for psoriasis with a proven safety profile [19][20][21]25] and has been used in a clinical trial for treating COVID-19 complications. Itolizumab is being used for compassionate treatment of patients with moderate to severe ARDS due to COVID-19 at several hospitals in India.…”

Keratinocyte-induced costimulation of human T cells through CD6 - but not CD2 - activates mTOR and prevents oxidative stress

“…Several clinical studies have demonstrated the efficacy of itolizumab, a humanized monoclonal antibody that selectively targets CD6, in the systemic treatment of moderate-to-severe psoriasis ( 64 – 66 ). Itolizumab binds to domain 1 of CD6 and inhibits T cell activation, proliferation, and secretion of proinflammatory cytokines involved in the pathogenesis of psoriasis ( 62 ).…”

CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies

“…Soon after, the mouse 12.1 mAb was used as an immunosuppressive agent in human kidney and bone marrow transplantation to prevent acute rejection based on its T-cell-depleting cytotoxic properties [52,53] (Table 1). Subsequently, the original mouse version (IOR-T1) of itolizumab, a humanised mAb against human CD6 currently approved for the treatment of psoriasis [54] (Table 1), was assayed for topical treatment of cutaneous T-cell lymphoma (CTCL) skin lesions [55] (Table 1). The humanised version of the non-depleting mouse anti-human CD6 UMCD6 mAb previously tested in experimental mouse models of autoimmune encephalitis and arthritis [30,66] has recently been tested in pre-clinical models of human T-cell lymphoma (TCL) [57] (Table 1).…”